Alex Bloom serves as VP Regulatory Affairs and Quality Assurance at Gyroscope Therapeutics, a UK-headquartered company focused on developing products and surgical delivery devices to preserve sight and fight the devastating impact of blindness. Gyroscopes leads investigational gene therapy, GT005, is in development to treat the leading cause of blindness, dry age-related macular degeneration (dry AMD). Prior to Gyroscope, Alex has spent the past decade working on the development and regulation of cell and gene therapies. He has worked on approximately 40 ATMP programs, including as the regulatory lead for Holoclar, the first stem cell-based medicine to receive approval in the EU / US. Prior to working in regulatory affairs, Alex spent time in manufacturing and process development positions for recombinant protein products. He received his PhD from the University of Sheffield (UK).